Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.

Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R.

Psychopharmacology (Berl). 2011 Dec;218(4):649-65. doi: 10.1007/s00213-011-2358-5. Epub 2011 Jun 15.

2.

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.

Griffiths RR, Richards WA, McCann U, Jesse R.

Psychopharmacology (Berl). 2006 Aug;187(3):268-83; discussion 284-92. Epub 2006 Jul 7.

PMID:
16826400
3.

Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.

Griffiths R, Richards W, Johnson M, McCann U, Jesse R.

J Psychopharmacol. 2008 Aug;22(6):621-32. doi: 10.1177/0269881108094300. Epub 2008 Jul 1.

4.

High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens.

Reissig CJ, Carter LP, Johnson MW, Mintzer MZ, Klinedinst MA, Griffiths RR.

Psychopharmacology (Berl). 2012 Sep;223(1):1-15. doi: 10.1007/s00213-012-2680-6. Epub 2012 Apr 13. Erratum in: Psychopharmacology (Berl). 2013 Aug;228(3):513.

5.

Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.

Garcia-Romeu A, Griffiths RR, Johnson MW.

Curr Drug Abuse Rev. 2014;7(3):157-64.

6.

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.

Barrett FS, Johnson MW, Griffiths RR.

J Psychopharmacol. 2015 Nov;29(11):1182-90. doi: 10.1177/0269881115609019. Epub 2015 Oct 6.

7.

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA.

J Psychopharmacol. 2016 Dec;30(12):1181-1197.

8.

Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.

MacLean KA, Johnson MW, Griffiths RR.

J Psychopharmacol. 2011 Nov;25(11):1453-61. doi: 10.1177/0269881111420188. Epub 2011 Sep 28.

9.

Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.

Griffiths RR, Johnson MW, Richards WA, Richards BD, Jesse R, MacLean KA, Barrett FS, Cosimano MP, Klinedinst MA.

J Psychopharmacol. 2018 Jan;32(1):49-69. doi: 10.1177/0269881117731279. Epub 2017 Oct 11.

10.
11.

Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.

Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX.

Biol Psychiatry. 2015 Oct 15;78(8):572-81. doi: 10.1016/j.biopsych.2014.04.010. Epub 2014 Apr 26.

PMID:
24882567
12.

Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.

Studerus E, Kometer M, Hasler F, Vollenweider FX.

J Psychopharmacol. 2011 Nov;25(11):1434-52. doi: 10.1177/0269881110382466. Epub 2010 Sep 20.

PMID:
20855349
13.
14.

Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates.

Barrett FS, Griffiths RR.

Curr Top Behav Neurosci. 2018;36:393-430. doi: 10.1007/7854_2017_474.

PMID:
28401522
15.

Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.

Carbonaro TM, Johnson MW, Hurwitz E, Griffiths RR.

Psychopharmacology (Berl). 2018 Feb;235(2):521-534. doi: 10.1007/s00213-017-4769-4. Epub 2017 Nov 7.

PMID:
29116367
16.

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.

Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL.

J Psychopharmacol. 2016 Dec;30(12):1165-1180.

17.

Alterations of consciousness and mystical-type experiences after acute LSD in humans.

Liechti ME, Dolder PC, Schmid Y.

Psychopharmacology (Berl). 2017 May;234(9-10):1499-1510. doi: 10.1007/s00213-016-4453-0. Epub 2016 Oct 7.

18.

Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum.

Johnson MW, MacLean KA, Reissig CJ, Prisinzano TE, Griffiths RR.

Drug Alcohol Depend. 2011 May 1;115(1-2):150-5. doi: 10.1016/j.drugalcdep.2010.11.005. Epub 2010 Dec 4.

19.

Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin.

Maclean KA, Leoutsakos JM, Johnson MW, Griffiths RR.

J Sci Study Relig. 2012 Dec;51(4):721-737.

20.

Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors.

Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX.

Biol Psychiatry. 2012 Dec 1;72(11):898-906. doi: 10.1016/j.biopsych.2012.04.005. Epub 2012 May 10.

PMID:
22578254

Supplemental Content

Support Center